NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard
Jazz committed $820 million at signing for an epilepsy drug with one early trial behind it. The justification is a regulatory pathway, not the data.
Neurology
NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It Yet
FDA approved the first medicine treating narcolepsy type 1 as a disease rather than a symptom set. Takeda cannot sell it for up to ninety days.
A Geneva BCI Company Records Its First Human Neural Data, and Europe Gets a Serious Entrant
ABILITY Neurotech recorded human neural data for the first time during tumour surgery in Munich, its first step toward a long-term implantable brain-computer interface.
The Only Non-Drug Pediatric ADHD Device Launches Its Second Generation Into a 1,500-Family Waitlist
The only FDA-cleared non-drug treatment for pediatric ADHD launched its second generation into a 1,500-family waitlist, with reimbursement still the open question.
JCR Gets Its Brain-Penetrating Hunter Therapy Out of Japan for the First Time, Through the UAE
IZCARGO, a therapy engineered to cross the blood-brain barrier, won its first marketing authorization outside Japan five years after launching there.
NeuroPulse Wk 29: First Brain Link Shares Movement Between Two People
The Alzheimer’s Association International Conference drove the week’s pipeline news, but the signal that mattered most came from a lab: the first brain link that let one paralysed person move and feel through another. Around it, a tau target validated and contested in the same week, an oral entrant scaling in Huntington’s, and anti-amyloid therapy fighting its real battle, which is access.
Lilly in advanced talks to buy Ventyx in a deal topping $1B
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1B, a move that would add inflammatory bowel disease and neurology assets.
NeuroPulse Today’s Signals: Personalized Neuromodulation, Pediatric Imaging Wins, and Schizophrenia IP Resets
NeuroPulse: Today’s Three Signals The neurology sector delivered three distinct signals today, spanning device-led personalization, regulatory expansion in pediatric imaging, and strategic recalibration in neuropsychiatric drug development. Together, they highlight how execution, not novelty, is increasingly determining momentum across neuroscience. Signal One: Soin Neuroscience and BIOTRONIK Push Spinal Cord Stimulation Toward Personalization Soin Neuroscience and … Read more
NeuroPulse Daily Brief: December 20, 2025
In Today’s NeuroPulse, the neurology sector advanced across multiple fronts, with fresh capital flowing into mental health drug development, early clinical milestones reached in brain cancer and neurodegeneration, and regulators extending approvals that lower risk in pediatric imaging and neuromodulation. From nine-figure biotech launches and oversubscribed neurotech seed rounds to first-in-human dosing, personalized spinal cord … Read more
NeuroPulse Today’s Signals: Precision Regulation, RNA Partnerships, and Real-World Data Redefine Neuro Strategy
NeuroPulse: Today’s Three Signals The neurology and neurodegeneration landscape is converging around execution rather than exploration. Today’s signals show how late-stage regulatory precision, platform-driven RNA partnerships, and regulator-grade real-world evidence are reshaping the path from discovery to durable market access. Across ALS, Alzheimer’s disease, and RNA-based therapeutics, stakeholders are tightening alignment between data, infrastructure, and … Read more